Walmart’s stock slides as U.S. sales are hit by falling drug prices

Walmart’s second-quarter results show how even the largest retailers are not immune to deflationary pressures. The company reported comparable U.S. sales growth of just 2.6% — its weakest print in over six years. Management pointed to falling drug prices as a key drag, since pharmacy sales are a significant component of same-store figures. While lower medication costs benefit consumers, they directly reduce the dollar value of Walmart’s transactions, weighing on revenue growth even as customer traffic holds up.

For investors, the development underscores a broader trend: drug-price deflation can distort retail earnings reports, making it harder to parse underlying demand. The stock slid on the news, reflecting disappointment after a long streak of stronger comps.

What to watch next is whether this deceleration is isolated to pharmacy or spreads to general merchandise. Also keep an eye on how Walmart adjusts pricing and promotions to defend margins, and whether management revises its full-year outlook. The key takeaway is that sales growth numbers alone can mask mix shifts — deflation in one category can flatter or flatter the headline depending on the quarter.